Elite Pharmaceuticals, Inc. Reports Financial Results for the First Quarter of Fiscal Year 2026 ended June 30, 2025 and Provides Conference Call Information
Elite Pharmaceuticals (OTCQB:ELTP) reported strong financial results for Q1 FY2026 ended June 30, 2025. The company achieved consolidated revenues of $40.2 million, marking a significant 114% increase compared to the same period last year. Operating profits surged to $21.7 million, representing a remarkable 462% growth year-over-year.
The exceptional performance was primarily driven by the successful launch of Elite's lisdexamfetamine products and robust growth across the Elite label product lines. The company has scheduled a conference call for August 15, 2025, at 11:30 AM EDT to discuss these results and provide business updates.
Elite Pharmaceuticals (OTCQB:ELTP) ha registrato risultati finanziari robusti per il primo trimestre dell'esercizio 2026 conclusosi il 30 giugno 2025. La societ脿 ha conseguito ricavi consolidati per 40,2 milioni di dollari, con un incremento significativo del 114% rispetto allo stesso periodo dell'anno precedente. I profitti operativi sono saliti a 21,7 milioni di dollari, segnando una crescita notevole del 462% su base annua.
Queste performance eccezionali sono state trainate principalmente dal lancio riuscito dei prodotti a base di lisdexamfetamina di Elite e dalla solida crescita delle linee di prodotti a marchio Elite. La societ脿 ha programmato una conference call per il 15 agosto 2025 alle 11:30 AM EDT per discutere i risultati e fornire aggiornamenti sull'attivit脿.
Elite Pharmaceuticals (OTCQB:ELTP) inform贸 s贸lidos resultados financieros del primer trimestre del ejercicio 2026, finalizado el 30 de junio de 2025. La compa帽铆a alcanz贸 ingresos consolidados de 40,2 millones de d贸lares, lo que supone un aumento significativo del 114% respecto al mismo per铆odo del a帽o anterior. Las ganancias operativas se dispararon hasta 21,7 millones de d贸lares, representando un notable crecimiento interanual del 462%.
El rendimiento excepcional se debi贸 principalmente al exitoso lanzamiento de los productos de lisdexanfetamina de Elite y al fuerte crecimiento de las l铆neas de productos con marca Elite. La empresa ha programado una conferencia telef贸nica para el 15 de agosto de 2025 a las 11:30 AM EDT para comentar estos resultados y ofrecer actualizaciones del negocio.
Elite Pharmaceuticals (OTCQB:ELTP)電� 2025雲� 6鞗� 30鞚茧 膦呺霅� 2026 須岅硠鞐半弰 1攵勱赴 鞁れ爜鞐愳劀 瓴“頃� 靹标臣毳� 氤搓碃頄堨姷雼堧嫟. 須岇偓電� 鞐瓣舶 毵れ稖 4,020毵� 雼煬毳� 旮半頄堨溂氅� 鞚措姅 鞝勲厔 霃欔赴 雽�牍� 114% 歃濌皜2,170毵� 雼煬搿� 旮夓頃橃棳 鞝勲厔 雽�牍� 462% 歃濌皜毳� 氤挫榾鞀惦媹雼�.
鞚� 臧欖潃 韮侅洈頃� 鞁れ爜鞚� 欤茧 Elite鞚� 毽姢雿膘偧韼橅儉氙�(lisdexamfetamine) 鞝滍拡 靹标车鞝� 於滌嫓鞕� Elite 敫岆灉霌� 鞝滍拡甑办潣 臧曧暅 靹膘灔鞐� 旮办澑頃╇媹雼�. 須岇偓電� 2025雲� 8鞗� 15鞚� 鞓れ爠 11鞁� 30攵�(霃欕秬 鞁滉皠) 須岅硠 鞁れ爜 氚� 靷梾 鞐呺嵃鞚错姼毳� 鞙勴暅 旖橅嵓霟办姢 旖滌潉 鞓堨爼頃橁碃 鞛堨姷雼堧嫟.
Elite Pharmaceuticals (OTCQB:ELTP) a annonc茅 de solides r茅sultats financiers pour le premier trimestre de l'exercice 2026 clos le 30 juin 2025. La soci茅t茅 a r茅alis茅 des revenus consolid茅s de 40,2 millions de dollars, soit une hausse significative de 114% par rapport 脿 la m锚me p茅riode de l'ann茅e pr茅c茅dente. Les b茅n茅fices d'exploitation ont grimp茅 脿 21,7 millions de dollars, repr茅sentant une croissance remarquable de 462% en glissement annuel.
Cette performance exceptionnelle a 茅t茅 principalement port茅e par le lancement r茅ussi des produits 脿 base de lisdexamf茅tamine d'Elite et par la forte croissance des gammes de produits sous la marque Elite. La soci茅t茅 a planifi茅 une conf茅rence t茅l茅phonique le 15 ao没t 2025 脿 11h30 EDT pour commenter ces r茅sultats et fournir des mises 脿 jour sur ses activit茅s.
Elite Pharmaceuticals (OTCQB:ELTP) meldete starke Finanzergebnisse f眉r das erste Quartal des Gesch盲ftsjahres 2026, das am 30. Juni 2025 endete. Das Unternehmen erzielte konsolidierte Ums盲tze von 40,2 Mio. USD, was einem deutlichen Anstieg von 114% gegen眉ber dem Vorjahreszeitraum entspricht. Das Betriebsergebnis stieg auf 21,7 Mio. USD und verzeichnete damit ein bemerkenswertes Wachstum von 462% im Jahresvergleich.
Die au脽ergew枚hnliche Leistung wurde haupts盲chlich durch die erfolgreiche Markteinf眉hrung der Lisdexamfetamin-Produkte von Elite und das starke Wachstum der Elite-Produktlinien getrieben. Das Unternehmen hat eine Telefonkonferenz f眉r den 15. August 2025 um 11:30 Uhr EDT angek眉ndigt, um diese Ergebnisse zu besprechen und gesch盲ftliche Updates zu geben.
- Revenue grew 114% year-over-year to $40.2 million
- Operating profits increased 462% to $21.7 million
- Successful launch of new lisdexamfetamine products
- Strong growth across Elite label product lines
- None.
Conference Call Scheduled for Friday, August 15 at 11:30 AM EDT
Northvale, New Jersey--(Newsfile Corp. - August 14, 2025) - Elite Pharmaceuticals, Inc. (OTCQB: ELTP) ("Elite" or the "Company"), a specialty pharmaceutical company developing niche generic products, announced results for the first quarter of fiscal year 2026 ended June 30, 2025 ("First Quarter").
Consolidated revenues for the three-month period ending June 30, 2025, were
Conference Call Information
Elite's management will host a conference call to discuss the First Quarter of Fiscal Year 2026 financial results and provide an update on recent business developments. Stockholder questions should be submitted to the company in advance of the call.
| Date: | August 15, 2025 |
| Time: | 11:30 AM EDT |
| Dial-in numbers: | 1-800-346-7359 (domestic) 1-973-528-0008 (international) |
| Conference number: | 98840 |
| Questions: | [email protected] Financial questions by 7:00 PM EDT on Thursday, August 14, 2025 |
| Audio Replay: |
The financial statements can be viewed for Elite's First Quarter of Fiscal Year 2026 on Form 10-Q
About Elite Pharmaceuticals, Inc.
Elite Pharmaceuticals, Inc. is a specialty pharmaceutical company that develops and distributes niche generic products. Elite specializes in developing, manufacturing, and distributing oral, controlled-release drug products. Elite owns multiple generic products, which it distributes nationally under the Elite Laboratories, Inc. label. Elite also has products licensed to TAGI Pharma. Elite operates a cGMP and DEA-registered research, development, and manufacturing facility in Northvale, NJ. For more information, visit .
This press release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, including, without limitation, those related to the effects, if any, on future results, performance or other expectations that may have some correlation to the subject matter of this press release. Readers are cautioned that such forward-looking statements involve, without limitation, risks, uncertainties and other factors not under the control of Elite, which may cause actual results, performance or achievements of Elite to be materially different from the results, performance or other expectations that may be implied by these forward-looking statements. These forward-looking statements may include statements regarding the expected timing of approval, if at all, of products by the FDA, and the actions the FDA may require of Elite in order to obtain such approvals. These forward-looking statements are not guarantees of future action or performance. These risks and other factors are discussed, without limitation, in Elite's filings with the Securities and Exchange Commission, including its reports on forms 10-K, 10-Q, and 8-K. Elite is under no obligation to update or alter its forward-looking statements, whether as a result of new information, future events or otherwise.
Contact:
For Elite Pharmaceuticals, Inc.
Dianne Will, Investor Relations, 518-398-6222
[email protected]
www.elitepharma.com
To view the source version of this press release, please visit
FAQ
What were Elite Pharmaceuticals (ELTP) Q1 FY2026 earnings?
How much did Elite Pharmaceuticals' revenue grow in Q1 2026?
What drove Elite Pharmaceuticals' growth in Q1 FY2026?
When is Elite Pharmaceuticals' Q1 2026 earnings call?
